This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 31 Jan 2020  |  North America

    Predictions for the Global Life Sciences Industry, 2020

    COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines

    The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

    $1,500.00
  2. 04 Nov 2019  |  North America

    Global Laboratory Products Purchasing Trends, 2019–2020

    An End-user Perspective on Laboratory Spending Reveals Modest 2020 Budget Increases Following Healthier 2019 Spending

    Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2019 that centered around the state of their laboratories in 2019 and their expectations for 2020. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year...

    $1,500.00
  3. 20 Mar 2019  |  North America

    2019 Predictions of the Global Life Sciences Industry

    As Novel Technologies Find Traction, Industry Focus Will Shift Towards Successful Monetization to Deliver Value-based Care

    he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

    $1,500.00
  4. 11 Feb 2019  |  North America

    Global Laboratory Products Purchasing Trends, 2018–2019

    An End-user Perspective on Laboratory Spending Reveals Modest 2019 Budget Increases Following Healthier 2018 Spending

    Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2018 that centered around the state of their laboratories in 2018 and their expectations for 2019. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year...

    $1,500.00
  5. 05 Oct 2018  |  North America

    US Point-of-Care Testing Infectious Disease Market, Forecast to 2022

    CLIA Waived Molecular POCT, Coupled with Upcoming Diseases Like Sepsis, Lyme Disease, New Strains of Influenza—H1, H3, and H7, will Drive Growth

    Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

    $1,500.00